IL325232A - מעכבי pi3k ושימוש בהם - Google Patents
מעכבי pi3k ושימוש בהםInfo
- Publication number
- IL325232A IL325232A IL325232A IL32523225A IL325232A IL 325232 A IL325232 A IL 325232A IL 325232 A IL325232 A IL 325232A IL 32523225 A IL32523225 A IL 32523225A IL 325232 A IL325232 A IL 325232A
- Authority
- IL
- Israel
- Prior art keywords
- pi3k inhibitors
- pi3k
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/36—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2023101669 | 2023-06-21 | ||
| PCT/CN2024/100794 WO2024260464A1 (en) | 2023-06-21 | 2024-06-21 | Pi3k inhibitors and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL325232A true IL325232A (he) | 2026-02-01 |
Family
ID=87473801
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL325232A IL325232A (he) | 2023-06-21 | 2025-12-09 | מעכבי pi3k ושימוש בהם |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN121358736A (he) |
| AU (1) | AU2024314618A1 (he) |
| IL (1) | IL325232A (he) |
| WO (1) | WO2024260464A1 (he) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR121719A1 (es) * | 2020-04-03 | 2022-06-29 | Petra Pharma Corp | Inhibidores alostéricos de cromenona del fosfoinosítido 3-quinasa (pi3k) para el tratamiento de enfermedades |
| KR20240014065A (ko) * | 2021-05-27 | 2024-01-31 | 페트라 파마 코포레이션 | 암의 치료를 위한 포스포이노시티드 3-키나제 (pi3k)의 알로스테릭 크로메논 억제제 |
| WO2023081209A1 (en) * | 2021-11-03 | 2023-05-11 | Zeno Management, Inc. | Pi3k inhibitors and methods of treating cancer |
| WO2023078401A1 (en) * | 2021-11-05 | 2023-05-11 | Fochon Biosciences, Ltd. | Compounds as protein kinase inhibitors |
| CN118742545A (zh) * | 2021-12-08 | 2024-10-01 | 南京征祥医药有限公司 | 作为PI3Kα抑制剂的稠合杂环化合物 |
| WO2023159155A1 (en) * | 2022-02-18 | 2023-08-24 | Pivalent Therapeutics, Inc. | Inhibitors of phosphoinositide 3-kinase (pi3k) and uses thereof |
-
2024
- 2024-06-21 AU AU2024314618A patent/AU2024314618A1/en active Pending
- 2024-06-21 WO PCT/CN2024/100794 patent/WO2024260464A1/en active Pending
- 2024-06-21 CN CN202480040645.XA patent/CN121358736A/zh active Pending
-
2025
- 2025-12-09 IL IL325232A patent/IL325232A/he unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024260464A1 (en) | 2024-12-26 |
| AU2024314618A1 (en) | 2026-01-08 |
| CN121358736A (zh) | 2026-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL325232A (he) | מעכבי pi3k ושימוש בהם | |
| IL325094A (he) | מעכבי pi3k-אלפא ושיטות לשימוש בהם | |
| SG11202107614PA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL312348A (he) | מעכבי hif-2alpha ושיטות השימוש בו | |
| SG11202107615TA (en) | Pcsk9 inhibitors and methods of use thereof | |
| IL287751A (he) | מעכבי kcnt1 ושיטות לשימוש | |
| IL324876A (he) | מעכבי parp1 והשימושים בהם | |
| SG11202112158YA (en) | Kcnt1 inhibitors and methods of use | |
| IL300107A (he) | מעכבי hsd17b13 קווינאזולינון ושימושים בהם | |
| IL287973A (he) | מעכבי acss2 ושיטות לשימושם | |
| EP4370124A4 (en) | PI3KA INHIBITORS AND METHODS OF USE THEREOF | |
| IL313636A (he) | תרכובות ושימוש בהן כמעכבי hdac6 | |
| IL264854A (he) | מעכבי spt5 ושיטות לשימוש בהם | |
| CA3251244A1 (en) | PI3K-ALPHA INHIBITORS AND THEIR METHODS OF USE | |
| IL283899A (he) | שילובים של מעכבי אינטראקציה hdm2-p53 ומעכב bcl2 ושימושם בטיפול במחלת הסרטן | |
| IL299700B1 (he) | מעכבי kcnt1 ושיטות לשימוש | |
| PL4337673T3 (pl) | Inhibitory psd-95 i ich zastosowania | |
| GB202214644D0 (en) | Sars-cov-2 mpro inhibitors and uses thereof | |
| IL310209A (he) | מעכבי rock2 ושימושים שלהם | |
| IL312466A (he) | מעכבי pi3k-אלפא ושיטות להכנה ולשימוש בהם | |
| IL305789A (he) | מעכבי usp30 ושימושים בהם | |
| EP4051669A4 (en) | SSAO INHIBITORS AND THEIR USE | |
| IL319049A (he) | מעכבי tyk2 ושימושים בהם | |
| GB202511417D0 (en) | Selective bet inhibitors and uses thereof | |
| CA3295342A1 (en) | Pi3k inhibitors and use thereof |